DaVita Inc. $DVA Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC reduced its stake in DaVita Inc. (NYSE:DVA) by 15.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,339 shares of the company’s stock after selling 5,383 shares during the quarter. Nisa Investment Advisors LLC’s holdings in DaVita were worth $5,307,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Berkshire Hathaway Inc acquired a new position in shares of DaVita during the 2nd quarter valued at about $6,425,269,000. BlackRock Inc. purchased a new stake in shares of DaVita in the second quarter valued at about $547,520,000. Bank of America Corp DE acquired a new stake in DaVita during the second quarter worth about $145,057,000. Bank of New York Mellon Corp acquired a new stake in DaVita during the second quarter worth about $101,127,000. Finally, Deutsche Bank AG purchased a new position in DaVita during the second quarter worth about $46,356,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Performance

DaVita stock opened at $183.55 on Friday. The company’s 50 day simple moving average is $180.60 and its 200-day simple moving average is $191.69. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The company has a market capitalization of $11.71 billion, a price-to-earnings ratio of 15.02, a price-to-earnings-growth ratio of 0.48 and a beta of 0.80.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. During the same quarter last year, the company posted $2.95 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts expect that DaVita Inc. will post 14.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, October 17th. Oppenheimer set a $220.00 price target on shares of DaVita in a report on Friday, August 7th. Truist Financial reduced their price target on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Barclays upped their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. Finally, UBS Group upped their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, DaVita currently has an average rating of “Moderate Buy” and a consensus price target of $233.43.

DaVita Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.